How Sentinel Lymph Node Biopsy is Impacting Adjuvant Radiation Treatment in Gynecologic Cancers

There is increasing use of sentinel lymph node biopsy in gynecologic cancers but how best to integrate this information into post-operative radiation treatment recommendations is not always clear. This includes how to interpret isolated tumor cells, micrometastasis, and macrometastasis. Providing up to date guidance on what to do in these situations is an important update for clinicians treating gynecologic cancers.

It is critical that radiation oncologists understand the growing role of sentinel lymph node biopsy in gynecologic cancers. This includes an understanding of the actual technique and the limitations of it. It also includes understanding how to interpret the results and how this impacts post-operative adjuvant treatment decisions. This activity provides an opportunity to improve knowledge and competence on this topic.

Topics:

  1. Integrating SLNBx Data in Vulvar Cancer
    Sushil Beriwal, MD, MBA, FASTRO
  2. Integrating SLNBx Data in Endometrial Cancer
    Christine Fisher, MD, MPH
  3. Integrating SLNBx Data in Cervical Cancer
    Jyoti Mayadev, MD, FASTRO
  4. Q and A
    Full Panel

This activity is available from November 26, 2024, through 11:59 p.m. Eastern time on November 25, 2026. 

The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons and residents.  

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Understand the data supporting sentinel lymph node biopsy in endometrial, cervical and vulvar cancers.
  • Determine best practices for how to integrate sentinel lymph node biopsy data into adjuvant radiation treatment recommendations. 
  • Learn the limitations of adjuvant radiation treatment decisions based on our current understanding. 
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
11/26/2024
Course expires: 
11/25/2026
Cost:
$149.00
Rating: 
0
  • Mitchell Kamrava, MD, MS, is employed by Cedars-Sinai Medical Center. Dr. Kamrava receives honoraria from Theragenics and compensation from Springer, Alessa, GammaTile and Adaptiiv. Dr. Kamrava is immediate past president of ADROP, is president-elect of the Board of Directors of ABS and is a gynecological oral examiner with ABR.  
  • Sushil Beriwal, MD, MBA, FASTRO, is employed by Allegheny Health Network Cancer Institute and Varian. Dr. Beriwal receives compensation/payment from Xoft and Elsevier.
  • Christine M. Fisher, MD, MPH, is employed by University of Colorado. Dr. Fisher is a Board Member of the American Brachytherapy Society and also serves on the NCCN Uterine and Cervical Cancer Guidelines Panel.  
  • Jyoti S. Mayadev, MD, FASTRO, is employed by University of California, San Diego. Dr. Mayadev receives honoraria from Varian Medical Systems, Merck, KORTUC, AstraZeneca, Agenus Bio and Primmune. Dr. Mayadev serves as Grant co-chair with NRG Oncology and is a Board Member of the American Brachytherapy Society.  

The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

Nonmember: $149
Member: $99
Member-in-Training: $49
Student/Graduate Student/PGY-1 Member: $49
Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.  

Policies:

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until November 25, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.